What is Xencor?
Founded in 1997 and headquartered in Pasadena, California, Xencor Inc. is dedicated to the development of innovative therapeutic antibodies and cytokine-based treatments. The company's scientific approach focuses on engineering these biological agents to enhance their efficacy and safety profiles for patients battling complex conditions such as cancer and autoimmune disorders. Xencor's strategic focus on antibody engineering positions it within the competitive biopharmaceutical landscape, aiming to address unmet medical needs through advanced biological therapies.
How much funding has Xencor raised?
Xencor has raised a total of $237.2M across 7 funding rounds:
Series B
$12.3M
Series C
$50M
Series D
$10M
Series E
$60M
Debt
$7.5M
Stock Offering
$72.4M
Share Placement
$25M
Series B (1999): $12.3M with participation from Stafford Capital Partners
Series C (2000): $50M led by Stafford Capital Partners, Sands Brothers Asset Management, and Moore Capital
Series D (2005): $10M supported by Zen Investments
Series E (2007): $60M featuring Oxford Bioscience Partners, Novo Nordisk, Zen Investments, MedImmune Ventures, and Merlin Nexus
Debt (2010): $7.5M, investors not publicly disclosed
Stock Issuance/Offering (2013): $72.4M, investors not publicly disclosed
Share Placement (2021): $25M, investors not publicly disclosed
Key Investors in Xencor
Oxford Bioscience Partners
Oxford Bioscience Partners is an international venture capital firm specializing in life science technology based investments, with offices in Boston, Massachusetts and Seoul, Korea.
MedImmune Ventures
MedImmune Ventures is a venture capital arm focused on investing in companies that align with MedImmune's strategic interests in biotechnology and pharmaceutical innovation.
Moore Capital
Moore Capital, LLC is committed to maximizing the value of our private equity investments as well as helping our partners achieve optimum success through a commitment to hard work, professional service, and confidentiality.
What's next for Xencor?
With a history of consistent capital infusion, including its most recent strategic investment, Xencor appears poised for a significant scaling phase. The company's enterprise-level funding context suggests a mature stage of development, likely Series A or beyond, enabling it to advance its clinical trials, expand its research and development capabilities, and potentially prepare for commercialization. The strategic nature of the recent financing indicates strong investor confidence in Xencor's technology and market potential, paving the way for accelerated growth and pipeline progression.
See full Xencor company page
